Lumea Honored with Four Major Awards for Innovation and Growth in Digital Pathology
Lumea, the U.S. leader in primary clinical digital pathology, is proud to announce it has received four prestigious awards this fall, recognizing the company’s rapid growth and transformative impact on cancer diagnostics. Lumea was named to the Inc. 5000 list, the Utah Business Fast 50 list, and won both a 2025 Global Recognition Award and a Utah Best of State award.
This quartet of accolades underscores Lumea’s unwavering commitment to innovation and its success in delivering efficient, affordable, and accessible digital pathology solutions. As the company continues to expand its global footprint, these awards validate its position at the forefront of healthcare technology.
“Being recognized with four distinct awards is a powerful testament to our team’s dedication and the profound impact of our technology,” said James Thackeray, CEO of Lumea. “Each award—from our rapid growth and local contributions to our global and state-level recognition—reflects our core mission: to improve patient outcomes by making cancer diagnostics faster, more accurate, and more accessible. We are honored by this recognition and remain focused on transforming the future of pathology.”
Acknowledging Growth and Innovation
Lumea’s inclusion on the Inc. 5000 list places it in the top half of the fastest-growing private companies in America, a prestigious ranking that has previously honored industry giants like Microsoft and Meta. The award highlights Lumea’s exceptional revenue growth over the past three years, a direct result of its innovative approach to digital pathology.
Similarly, Lumea’s place on the Utah Business Fast 50 list celebrates its sustained revenue growth and significant contribution to Utah’s thriving economy. This local recognition reinforces Lumea’s role as a key player within the state’s innovative business landscape, creating high-paying STEM jobs and supporting the community.
The 2025 Global Recognition Award was given for Lumea’s success in reshaping diagnostic practices worldwide. The company’s patented technologies, such as the BxBoard® and BxChip®, have demonstrably improved tissue care and increased cancer detection rates by 18.9%. These innovations have been adopted by hundreds of laboratories across five continents.
Finally, the Utah Best of State award in the Medical Processes category recognizes Lumea for its leadership in transforming how biopsies are handled and diagnosed. The award highlights the company’s ability to dramatically shorten diagnostic turnaround times from weeks to as little as 3–4 days, significantly reducing the anxious wait for patients and their families.
About Lumea
Lumea is a leader in digital pathology, empowering efficient, affordable, and accessible cancer diagnostics through simplified, workflow-driven innovation. With over a decade of expertise, Lumea has set the standard for efficiency and quality. The company’s comprehensive platform, including its tissue-handling technology and a best-in-class viewer with AI-driven workflows, supports over half of the U.S. urology market and top dermatology and gastroenterology groups. By placing patients at the core of its mission, Lumea is transforming pathology for a more precise and efficient future. Learn more at https://lumeadigital.com.
SOURCE: Lumea
